Cologne, Germany: Cellbox Solutions, a warm-chain logistics technology company focused on enabling the global transport of living cells under controlled physiological conditions, has announced the first closing of its Series A financing round.
Cellbox Solutions raised approximately €3.5 million, with the investment round led by digital business angel network Companisto, alongside existing investors including NRW.BANK.
The fresh funding will enable Cellbox Solutions to expand international production and sales operations while unlocking new application areas, particularly in cell and gene therapy and in vitro fertilization (IVF). The Series A round remains open for additional tranches until May 2026.
The financing milestone marks a significant step in the growth journey of Cellbox Solutions, which is developing technology that ensures the safe and reliable transportation of living cell samples.
The company’s patented warm-chain logistics platform is designed to maintain controlled physiological conditions during transit, addressing a critical requirement in the life sciences ecosystem.
Also Read: Nafithromycin: India’s First Home-Grown Antibiotic Marks Breakthrough in Biotech Innovation
Advancing Warm-Chain Logistics for Living Cell Transport
Cellbox Solutions develops Cellbox portable CO₂ incubators, which allow living cell samples to be transported safely while maintaining stable physiological conditions.
The company’s patented warm-chain technology enables controlled shipment conditions for up to 48 hours, ensuring the preservation of cell viability and functionality during transit.
The devices are certified and compliant with IATA regulations for air transport, allowing them to be used in international logistics networks.
Currently, more than 300 Cellbox devices are deployed globally, serving customers across the pharmaceutical and biotechnology industries, applied research institutions, and universities.
By enabling consistent and reproducible transport conditions, Cellbox Solutions aims to address logistical challenges associated with the movement of sensitive biological materials across clinical and research environments.
Leadership Expansion to Drive International Growth
As part of its growth strategy, Cellbox Solutions has strengthened its management team with the appointment of Dr Bernd Muehlenweg as Chief Business Officer (CBO) and Chief Financial Officer (CFO).
Dr. Muehlenweg brings more than 20 years of international experience in the life sciences industry. Prior to joining Cellbox Solutions, he served as Senior Vice President and Global Head of Business Development, Cell Therapy at Evotec, where he led international commercial and strategic partnership initiatives in the advanced therapy sector.
Commenting on the company’s growth trajectory, Dr. Bernd Muehlenweg said: “Cellbox is setting a new benchmark in the transportation of living cells. By enabling safe, controlled, and reproducible transport under physiological conditions, we address a critical bottleneck in the life sciences industry. The investment round marks an important milestone in expanding our international footprint and establishing Cellbox as a global infrastructure standard for living cell shipment and warm-chain logistics.
Our patented platform and strong regulatory positioning provide an excellent foundation for global scale-up across multiple life sciences applications, including the rapidly growing field of cell and gene therapies. I look forward to further strengthening our commercial operations, expanding our service portfolio, and building the organizational structures required to support the next phase of international growth.”
Also Read: Fermenta Biotech Granted Patent for Sustainable Plant-Based Vitamin D3 Manufacturing
Cellbox Solutions: Investors Back Scalable Logistics Platform
According to Companisto, the investment reflects confidence in the company’s potential to reshape the life sciences logistics landscape.
Dr. Robin Ghosh, Investment Manager at Companisto, stated: “Cellbox addresses a structural gap in the life sciences value chain: the reliable transport of living cells at physiological conditions. As advanced therapies scale globally, logistics becomes a critical success factor. We view Cellbox not as an incremental product innovation, but as a scalable platform with the potential to redefine how sensitive biological materials are transported across research and clinical environments.”
Companisto will also support Cellbox Solutions in its growth phase by contributing strategic expertise alongside financial investment. As a digitalized business angel network, the organization aims to facilitate international scaling and strategic expansion.
Vision for Global Warm-Chain Infrastructure
Prof. Dr. Kathrin Adlkofer, Founder and CEO of Cellbox Solutions, emphasized the company’s long-term mission to transform the transportation of living cells globally.
“Our vision is to redefine how living cells are transported globally. With the continued support of our investors and the strengthening of our leadership team with a highly experienced executive, we are building the foundation for long-term international growth and expanding the reach of warm-chain logistics across clinical and research applications. We are convinced that reliable live-cell transport will become an essential component of the global life sciences value chain.”
Looking ahead, Cellbox Solutions aims to establish warm-chain logistics as the preferred global standard for transporting living cells, cell therapies, and other sensitive biological materials.
